Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
UBS
Boehringer Ingelheim
Federal Trade Commission
Johnson and Johnson
McKinsey

Generated: September 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,923,564

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,923,564 protect, and when does it expire?

Patent 7,923,564 protects NUPLAZID and is included in two NDAs.

This patent has forty-eight patent family members in seventeen countries.

Summary for Patent: 7,923,564
Title:Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
Abstract: Disclosed herein are methods for synthesizing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide. Also disclosed herein is the hemi-tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates.
Inventor(s): Thygesen; Mikkel Boas (Copenhagen East, DK), Schlienger; Nathalie (Frederiksberg, DK), Tolf; Bo-Ragnar (Malmo, SE), Andersson; Carl-Magnus A. (Hjarup, SE), Blatter; Fritz (Reinach, CH), Berghausen; Jorg (Lorrach, DE)
Assignee: ACADIA Pharmaceuticals, Inc. (San Diego, CA)
Application Number:12/795,547
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,923,564

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acadia Pharms Inc NUPLAZID pimavanserin tartrate CAPSULE;ORAL 210793-001 Jun 28, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-002 Jun 28, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Teva
Daiichi Sankyo
Covington
US Department of Justice
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.